Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche and Celldex to test drug combo in renal cell carcinoma

This article was originally published in Scrip

Executive Summary

Roche has signed a deal with Celldex Therapeutics to test its immunotherapy MPDL3280A (also known as anti-PDL1 and RG7446) with Celldex's varlilumab, a CD27 targeting antibody, in a Phase I/II study in renal cell carcinoma. Varlilumab is currently being studied in two Phase I/II combination studies and more combination studies are planned. Celldex the latest trial was supported by promising signs of single-agent activity observed in a Phase I study in renal cell carcinoma. The company believes that combining an immune activator with a checkpoint inhibitor in this disease setting could augment this activity. Roche, which has US FDA breakthrough therapy designation for MPDL3280A in bladder cancer and NSCLC, has already presented preliminary clinical data of a combination of MPDL3280A with Avastin in first line metastatic renal cell carcinoma.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028153

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel